You can buy or sell BeiGene and other stocks, options, ETFs, and crypto commission-free!
BeiGene, Ltd. American Depositary Shares, also called BeiGene, is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. Read More It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
52 Week High
52 Week Low
The Motley FoolMar 22
3 Key Takeaways From BeiGene's CEO
China's biotechnology industry is booming. The world's most populous country is going all-in on bringing innovative new drugs to market, flooding the sector with capital, political support, and key talent. China expects its biotech sector to represent 4% of its GDP by 2020, which could be worth $500 billion by the end of next year. With numbers that large, healthcare investors need to take notice. But biotech has also traditionally been a very risky investment. Stock prices can soar or crash based on the b...
Stock Price, News, & Analysis for Beigene
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte le...
Yahoo FinanceMar 6
BRIEF-Ambrx And Beigene Announce Global Research And Development Collaboration To Develop Next-Generation Biologics
March 6 (Reuters) - Beigene Ltd: * AMBRX AND BEIGENE ANNOUNCE GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION TO DEVELOP NEXT-GENERATION BIOLOGICS * BEIGENE LTD - UNDER TERMS, AMBRX WILL RECEIVE AN UPFRONT PAYMENT OF US$10 MILLION TO FUND INITIAL DISCOVERY AND RESEARCH ACTIVITIES * BEIGENE LTD - AMBRX TO ALSO RECEIVE ADDITIONAL UPFRONT PAYMENTS OF UP TO US$19 MILLION IF BEIGENE ELECTS TO INITIATE ADDITIONAL PROGRAMS * BEIGENE - AMBRX ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT, REGULATORY, SALES-BASED MILES...
Expected May 8, After Hours